Knowde Enhanced TDS
Identification & Functionality
- Ingredient Name
- Food Ingredients Functions
- Pharma & Nutraceuticals Functions
- Ingredients
- Bifidobacterium Lactis, Biotin, Lactobacillus Acidophilus, Lactobacillus Salivarius, Lactobacillus Casei, Bifidobacterium Bifidum, Vitamin B2
Features & Benefits
- Food Ingredients Features
- Product Background
Worldwide, the prevalence of allergic diseases is rising dramatically in both developed and developing countries. In spite of this escalation, even in the developed world, treatment options for patients with allergic diseases are far from ideal.1-3
Allergic diseases are caused by hypersensitivity of the immune system to harmful substances in the environment. Major allergic diseases include asthma, food allergies, allergic rhinitis (AR) and atopic dermatitis (AD) or eczema. Worldwide, AR currently affects between 10% and 30% of the population and studies indicate that prevalence rates are increasing. AD affects nowadays 15-30% of children and 2-10% of adults.4 Allergic diseases have a high morbidity, are responsible for a substantial proportion of health service use, and are accompanied by a severely reduced quality of life.5
It is not completely clear what triggers the dramatic increase in incidence of allergies, but many theories postulate the involvement of (Westernized) lifestyle, environment and (missing) microbes.6,7 Moreover, the World Allergy Organization and clinical studies reveal that a reduced biodiversity and alterations in the composition of the gut and skin microbiota are associated with various inflammatory conditions, including asthma and allergy.8 Thus, a potential approach to manage allergic symptoms could be the administration of specifically selected probiotic strains.
Figure 1: Major changes in microbial exposure in the first half of the century are believed to trigger the accelerating increase in allergic diseases.
- Strain Selection
Ecologic® ALLERGYCARE is a multispecies probiotic formulation consisting of 6 specially selected probiotic strains. Probiotic strains can exert health effects at different levels in the gut (see figure 2). The probiotic strains of Ecologic® ALLERGYCARE have been selected to influence the immune system (level 3). The strains have been screened in vitro for their capacity to:
• Modulate production of immunosuppressive cytokines by;
- induction of IL-10 and IFN-y
- reduction of IL-4, IL-5 and IL-13.
Applications & Uses
- Markets
- Food & Nutrition Applications
Properties
Regulatory & Compliance
- Certifications & Compliance
Technical Details & Test Data
- Clinically Evidence
The effect of Ecologic® ALLERGYCARE on AD symptoms has been tested in a doubleblind, randomized, placebo-controlled human trial, performed by Harran University, Turkey9 . Forty children between 1-13 years of age suffering from AD received 2x109 CFU Ecologic® ALLERGYCARE or placebo twice daily for eight weeks. Both clinical and mechanistic effects were measured at baseline and at the end of the intervention period. Ecologic® ALLERGYCARE significantly reduced the SCORing Atopic Dermatitis (SCORAD) index.(see figure 3). These results are supported by the finding that total IgE levels were significantly dropped in the probiotic group, compared to the placebo group. The effect of Ecologic® ALLERGYCARE on quality of life (QoL) in patients with AR has been tested in a clinical trial performed by Griffith University Australia10,11. Forty hay fever patients received 2x109 CFU Ecologic® ALLERGYCARE twice daily for eight weeks. Before and after the intervention period, QoL was determined using the rhinitis quality of life questionnaire (RQLQ). During the intervention patients also recorded AR symptoms and medication use. Ecologic® ALLERGYCARE significantly improved QoL in 63% of the patients (meaningful improvement >0.7 decrease in the RQLQ, p=0.005). The average RQLQ score dropped from 2.83 at baseline to 1.66 at midpoint to 1.38 at week 8 (see figure 4). In line with these findings, a trend towards reduction in AR symptoms and medication use was found.
Figure 3: Changes in the SCORAD-index before and after the intervention. * Significant decrease, p=0.005.
Figure 4: RQLQ scores during the intervention. * Significant decrease, p=0.005.
